May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Evaluating Adherence and Readiness for Behavior Change in Patients Prescribed Ocular Hypotensive Therapy
Author Affiliations & Notes
  • G. F. Schwartz
    Glaucoma Consultants, Baltimore, Maryland
  • K. Plake
    Purdue University School of Pharmacy and Pharmaceutical Sciences, West Lafayette, Indiana
  • M. A. Mychaskiw
    Pfizer Inc, New York, New York
  • Footnotes
    Commercial Relationships  G.F. Schwartz, Pfizer, Allergan, F; Pfizer, C; Pfizer, R; K. Plake, Pfizer, C; M.A. Mychaskiw, Pfizer, E.
  • Footnotes
    Support  Research supported by Pfizer Inc.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4983. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. F. Schwartz, K. Plake, M. A. Mychaskiw; Evaluating Adherence and Readiness for Behavior Change in Patients Prescribed Ocular Hypotensive Therapy. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4983. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To compare responses in two patient populations to a questionnaire developed to identify those prescribed ocular hypotensive (OH) medication whose adherence may need improvement and who may be ready to change .

Methods: : The content/face validity of a 62-item, self-administered questionnaire based on the Transtheoretical Model of Change was confirmed by 9 glaucoma specialists. Questions related to demographics, visual function, health and medications, and use of/problems with OH therapies. The instrument was given anonymously to 202 patients prescribed ≥1 OH medication and with no history of trabeculectomy - 102 from a tertiary metropolitan glaucoma referral practice (Group 1), 100 from a more rural multispecialty ophthalmology practice (Group 2).

Results: : Those in Group 1 were younger (<60 years: 36.3% vs 21.5%), less likely to be Caucasian (65.3% vs 81.4%), and better educated (≤high school/GED: 20.1% vs 54.7%); P<0.05 for all 3 between-group differences. In both groups, >80% had glaucoma, >60% were diagnosed >3 years previously, and >70% expected to take eyedrops for the rest of their lives. The majority (Groups 1, 2: 86.6%, 92.6%) reported administering eyedrops every day, although more in Group 2 reported administering eyedrops at the same time every day (78.6%, 91.6%; P<0.05). Groups were similar with regard to mean number of adherence problems (0.92±1.08, 1.07±2.52) and mean adherence scores (23.98±1.29, 23.77±2.54). Common barriers to adherence were forgetting when the regular schedule changed (14.7%, 10.3%), forgetting when traveling (13.7%, 19.6%), and falling asleep (19.6%, 15.5%). In Group 1, the number of adherence problems was correlated with adherence score (r=-0.611, P<0.0001) and number of side effects (r=0.349, P<0.0001).

Keywords: clinical (human) or epidemiologic studies: health care delivery/economics/manpower • clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: risk factor assessment 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.